banner add

Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices

In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it.

from NYT > Health https://ift.tt/NWShtOr
via IFTTT

No comments

RFK Jr. Allies Target States to Overturn Vaccine Mandates for Schools

Proponents of vaccines warn that the efforts will further dismantle the immunization infrastructure and lead to more outbreaks of disease. ...

Theme images by PLAINVIEW. Powered by Blogger.